Biomarkers of Acromegaly and Growth Hormone Action.
GH deficit
Growth hormone
acromegaly
biomarkers
insulin-like growth factor-I
miRNA
Journal
Protein and peptide letters
ISSN: 1875-5305
Titre abrégé: Protein Pept Lett
Pays: Netherlands
ID NLM: 9441434
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
12
2019
revised:
16
03
2020
accepted:
20
03
2020
pubmed:
21
4
2020
medline:
5
2
2021
entrez:
21
4
2020
Statut:
ppublish
Résumé
Biological markers (biomarkers) play a key role in drug development, regulatory approval and clinical care of patients and are linked to clinical and surrogate outcomes. Both acromegaly and Growth Hormone Deficiency (GHD) are pathological conditions related to important comorbidities that, in addition to having stringent diagnostic criteria, require valid markers for the definition of treatment, treatment monitoring and follow-up. GH and insulin-like growth factor-I (IGF-I) are the main biomarkers of GH action in children and adults while, in acromegaly, both GH and IGF-I are established biomarkers of disease activity. However, although GH and IGF-I are widely validated biomarkers of GHD and acromegaly, their role is not completely exhaustive or suitable for clinical classification and follow-up. Therefore, new biological markers for acromegaly and GH replacement therapy are strongly needed. The aim of this paper is to review and summarize the current state in the field pointing out new potential biomarkers for acromegaly and GH use/abuse.
Identifiants
pubmed: 32310036
pii: PPL-EPUB-105921
doi: 10.2174/0929866527666200420103816
doi:
Substances chimiques
Biomarkers
0
IGF1 protein, human
0
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231-1245Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.